Which has stronger earnings & valuation, HCM or CRNX?

HUTCHMED has higher revenue and earnings than Crinetics Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $548.51M 4.35 $456.91M N/A N/A Crinetics Pharmaceuticals $7.70M 1,170.54 -$465.32M -$5.04 N/A

Which has preferable valuation & earnings, BLTE or HCM?

HUTCHMED has higher revenue and earnings than Belite Bio. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Belite Bio N/A N/A -$77.61M -$2.73 N/A HUTCHMED $548.51M 4.35 $456.91M N/A N/A

Is BLTE or HCM more profitable?

HUTCHMED's return on equity of 0.00% beat Belite Bio's return on equity. Company Net Margins Return on Equity Return on Assets Belite Bio N/A -11.84% -11.62% HUTCHMED N/A N/A N/A

Does the media prefer BLTE or HCM?

In the previous week, Belite Bio and Belite Bio both had 2 articles in the media. Belite Bio's average media sentiment score of 0.77 beat HUTCHMED's score of 0.74 indicating that Belite Bio is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HUTCHMED 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher earnings & valuation, LNTH or HCM?

HUTCHMED has lower revenue, but higher earnings than Lantheus. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lantheus $1.54B 4.26 $233.56M $4.14 24.29 HUTCHMED $548.51M 4.35 $456.91M N/A N/A

Is LNTH or HCM more profitable?

Lantheus has a net margin of 17.69% compared to HUTCHMED's net margin of 0.00%. Lantheus' return on equity of 28.10% beat HUTCHMED's return on equity. Company Net Margins Return on Equity Return on Assets Lantheus 17.69% 28.10% 14.35% HUTCHMED N/A N/A N/A

Does the media refer more to LNTH or HCM?

In the previous week, HUTCHMED had 1 more articles in the media than Lantheus. MarketBeat recorded 2 mentions for HUTCHMED and 1 mentions for Lantheus. Lantheus' average media sentiment score of 0.84 beat HUTCHMED's score of 0.74 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HUTCHMED 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings and valuation, LQDA or HCM?

HUTCHMED has higher revenue and earnings than Liquidia. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Liquidia $158.32M 37.81 -$68.92M $1.37 48.82 HUTCHMED $548.51M 4.35 $456.91M N/A N/A

Is LQDA or HCM more profitable?

Liquidia has a net margin of 30.74% compared to HUTCHMED's net margin of 0.00%. Liquidia's return on equity of 149.65% beat HUTCHMED's return on equity. Company Net Margins Return on Equity Return on Assets Liquidia 30.74% 149.65% 36.30% HUTCHMED N/A N/A N/A

Does the media prefer LQDA or HCM?

In the previous week, Liquidia had 9 more articles in the media than HUTCHMED. MarketBeat recorded 11 mentions for Liquidia and 2 mentions for HUTCHMED. Liquidia's average media sentiment score of 0.74 beat HUTCHMED's score of 0.74 indicating that Liquidia is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Liquidia 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive HUTCHMED 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, HCM or AMRX?

HUTCHMED has higher earnings, but lower revenue than Amneal Pharmaceuticals. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio HUTCHMED $548.51M 4.35 $456.91M N/A N/A Amneal Pharmaceuticals $3.02B 1.98 $72.06M $0.49 38.18

Does the media refer more to HCM or AMRX?

In the previous week, Amneal Pharmaceuticals had 9 more articles in the media than HUTCHMED. MarketBeat recorded 11 mentions for Amneal Pharmaceuticals and 2 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.74 beat Amneal Pharmaceuticals' score of 0.49 indicating that HUTCHMED is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment HUTCHMED 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amneal Pharmaceuticals 3 Very Positive mention(s) 3 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

HUTCHMED (HCM) Competitors

$13.67 -0.15 (-1.09%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$13.64 -0.03 (-0.25%)

As of 09/18/2026 07:30 PM Eastern

Compare

HCM vs. CRNX, BLTE, LNTH, LQDA, and AMRX

Should you buy HUTCHMED stock or one of its competitors? HUTCHMED's main competitors and comparable companies include Crinetics Pharmaceuticals (CRNX), Belite Bio (BLTE), Lantheus (LNTH), Liquidia (LQDA), and Amneal Pharmaceuticals (AMRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does HUTCHMED compare to Crinetics Pharmaceuticals?

HUTCHMED (NASDAQ:HCM) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, dividends, media sentiment, analyst recommendations, institutional ownership, earnings, risk and profitability.

8.8% of HUTCHMED shares are owned by institutional investors. Comparatively, 98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 3.6% of HUTCHMED shares are owned by insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

HUTCHMED has a net margin of 0.00% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. HUTCHMED's return on equity of 0.00% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

HUTCHMED presently has a consensus price target of $14.87, suggesting a potential upside of 8.75%. Crinetics Pharmaceuticals has a consensus price target of $81.00, suggesting a potential downside of 4.65%. Given HUTCHMED's stronger consensus rating and higher possible upside, equities research analysts clearly believe HUTCHMED is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.43
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.24

HUTCHMED has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.08, suggesting that its share price is 92% less volatile than the broader market.

HUTCHMED has higher revenue and earnings than Crinetics Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	4.35	$456.91M	N/A	N/A
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A

In the previous week, HUTCHMED had 2 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 2 mentions for HUTCHMED and 0 mentions for Crinetics Pharmaceuticals. HUTCHMED's average media sentiment score of 0.74 beat Crinetics Pharmaceuticals' score of 0.00 indicating that HUTCHMED is being referred to more favorably in the media.

Company	Overall Sentiment
HUTCHMED	Positive
Crinetics Pharmaceuticals	Neutral

Summary

HUTCHMED beats Crinetics Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does HUTCHMED compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and HUTCHMED (NASDAQ:HCM) are both mid-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Belite Bio has a beta of -1.23, indicating that its share price is 223% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market.

HUTCHMED's return on equity of 0.00% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
HUTCHMED	N/A	N/A	N/A

HUTCHMED has higher revenue and earnings than Belite Bio.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
HUTCHMED	$548.51M	4.35	$456.91M	N/A	N/A

Belite Bio presently has a consensus target price of $218.73, suggesting a potential upside of 27.94%. HUTCHMED has a consensus target price of $14.87, suggesting a potential upside of 8.75%. Given Belite Bio's stronger consensus rating and higher possible upside, equities analysts plainly believe Belite Bio is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
HUTCHMED	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.43

0.5% of Belite Bio shares are owned by institutional investors. Comparatively, 8.8% of HUTCHMED shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 3.6% of HUTCHMED shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Belite Bio and Belite Bio both had 2 articles in the media. Belite Bio's average media sentiment score of 0.77 beat HUTCHMED's score of 0.74 indicating that Belite Bio is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HUTCHMED	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

HUTCHMED beats Belite Bio on 7 of the 12 factors compared between the two stocks.

How does HUTCHMED compare to Lantheus?

Lantheus (NASDAQ:LNTH) and HUTCHMED (NASDAQ:HCM) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, media sentiment, valuation, earnings, institutional ownership, analyst recommendations and dividends.

99.1% of Lantheus shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 3.6% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Lantheus has a beta of -0.03, meaning that its stock price is 103% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market.

Lantheus has a net margin of 17.69% compared to HUTCHMED's net margin of 0.00%. Lantheus' return on equity of 28.10% beat HUTCHMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
HUTCHMED	N/A	N/A	N/A

In the previous week, HUTCHMED had 1 more articles in the media than Lantheus. MarketBeat recorded 2 mentions for HUTCHMED and 1 mentions for Lantheus. Lantheus' average media sentiment score of 0.84 beat HUTCHMED's score of 0.74 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HUTCHMED	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Lantheus currently has a consensus price target of $108.11, indicating a potential upside of 7.52%. HUTCHMED has a consensus price target of $14.87, indicating a potential upside of 8.75%. Given HUTCHMED's stronger consensus rating and higher possible upside, analysts plainly believe HUTCHMED is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.29
HUTCHMED	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.43

HUTCHMED has lower revenue, but higher earnings than Lantheus.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.26	$233.56M	$4.14	24.29
HUTCHMED	$548.51M	4.35	$456.91M	N/A	N/A

Summary

HUTCHMED beats Lantheus on 8 of the 15 factors compared between the two stocks.

How does HUTCHMED compare to Liquidia?

Liquidia (NASDAQ:LQDA) and HUTCHMED (NASDAQ:HCM) are both mid-cap healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, earnings, risk, dividends, analyst recommendations, media sentiment, institutional ownership and valuation.

Liquidia has a beta of 0.53, suggesting that its share price is 47% less volatile than the broader market. Comparatively, HUTCHMED has a beta of 0.24, suggesting that its share price is 76% less volatile than the broader market.

64.5% of Liquidia shares are held by institutional investors. Comparatively, 8.8% of HUTCHMED shares are held by institutional investors. 25.6% of Liquidia shares are held by insiders. Comparatively, 3.6% of HUTCHMED shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Liquidia had 9 more articles in the media than HUTCHMED. MarketBeat recorded 11 mentions for Liquidia and 2 mentions for HUTCHMED. Liquidia's average media sentiment score of 0.74 beat HUTCHMED's score of 0.74 indicating that Liquidia is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Liquidia	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
HUTCHMED	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Liquidia presently has a consensus target price of $98.08, indicating a potential upside of 46.66%. HUTCHMED has a consensus target price of $14.87, indicating a potential upside of 8.75%. Given Liquidia's stronger consensus rating and higher probable upside, equities research analysts clearly believe Liquidia is more favorable than HUTCHMED.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Liquidia	2 Sell rating(s)	3 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.45
HUTCHMED	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.43

Liquidia has a net margin of 30.74% compared to HUTCHMED's net margin of 0.00%. Liquidia's return on equity of 149.65% beat HUTCHMED's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Liquidia	30.74%	149.65%	36.30%
HUTCHMED	N/A	N/A	N/A

HUTCHMED has higher revenue and earnings than Liquidia.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Liquidia	$158.32M	37.81	-$68.92M	$1.37	48.82
HUTCHMED	$548.51M	4.35	$456.91M	N/A	N/A

Summary

Liquidia beats HUTCHMED on 12 of the 14 factors compared between the two stocks.

How does HUTCHMED compare to Amneal Pharmaceuticals?

HUTCHMED (NASDAQ:HCM) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, media sentiment, valuation, dividends, risk, institutional ownership, analyst recommendations and profitability.

In the previous week, Amneal Pharmaceuticals had 9 more articles in the media than HUTCHMED. MarketBeat recorded 11 mentions for Amneal Pharmaceuticals and 2 mentions for HUTCHMED. HUTCHMED's average media sentiment score of 0.74 beat Amneal Pharmaceuticals' score of 0.49 indicating that HUTCHMED is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
HUTCHMED	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amneal Pharmaceuticals	3 Very Positive mention(s)	3 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

8.8% of HUTCHMED shares are held by institutional investors. Comparatively, 31.8% of Amneal Pharmaceuticals shares are held by institutional investors. 3.6% of HUTCHMED shares are held by insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

HUTCHMED has higher earnings, but lower revenue than Amneal Pharmaceuticals.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
HUTCHMED	$548.51M	4.35	$456.91M	N/A	N/A
Amneal Pharmaceuticals	$3.02B	1.98	$72.06M	$0.49	38.18

HUTCHMED currently has a consensus price target of $14.87, suggesting a potential upside of 8.75%. Amneal Pharmaceuticals has a consensus price target of $20.14, suggesting a potential upside of 7.66%. Given HUTCHMED's higher possible upside, analysts plainly believe HUTCHMED is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
HUTCHMED	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.43
Amneal Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.89

Amneal Pharmaceuticals has a net margin of 5.05% compared to HUTCHMED's net margin of 0.00%. HUTCHMED's return on equity of 0.00% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
HUTCHMED	N/A	N/A	N/A
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

HUTCHMED has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market.

Summary

Amneal Pharmaceuticals beats HUTCHMED on 9 of the 15 factors compared between the two stocks.

Get HUTCHMED News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding HCM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

HCM vs. The Competition

Export

Metric	HUTCHMED	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.38B	$12.47B	$7.24B	$13.19B
Dividend Yield	N/A	2.64%	2.57%	12.81%
P/E Ratio	N/A	792.21	274.93	25.38
Price / Sales	4.35	753.62	646.01	89.45
Price / Cash	5.07	86.36	76.25	51.42
Price / Book	1.91	10.53	10.46	6.33
Net Income	$456.91M	$2.82B	$3.49B	$358.33M
7 Day Performance	6.63%	1.69%	0.59%	1.12%
1 Month Performance	8.58%	0.83%	-2.01%	-2.67%
1 Year Performance	-19.78%	3.90%	18.09%	6.01%

HUTCHMED Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
HCM HUTCHMED	1.7222 of 5 stars	$13.67 -1.1%	$14.87 +8.8%	-21.7%	$2.38B	$548.51M	N/A	1,796
CRNX Crinetics Pharmaceuticals	1.0057 of 5 stars	$84.95 flat	$81.00 -4.6%	N/A	$9.01B	$7.70M	N/A	210
BLTE Belite Bio	3.662 of 5 stars	$169.12 -2.2%	$218.73 +29.3%	+133.4%	$6.81B	N/A	N/A	41
LNTH Lantheus	3.8013 of 5 stars	$100.44 +0.1%	$108.11 +7.6%	+95.0%	$6.56B	$1.54B	24.26	1,193
LQDA Liquidia	3.9235 of 5 stars	$63.08 -3.4%	$98.08 +55.5%	+171.1%	$5.64B	$158.32M	45.96	216	Insider Trade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:HCM) was last updated on 9/19/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

HUTCHMED (HCM) Competitors

HCM vs. CRNX, BLTE, LNTH, LQDA, and AMRX

How does HUTCHMED compare to Crinetics Pharmaceuticals?

Summary

How does HUTCHMED compare to Belite Bio?

Summary

How does HUTCHMED compare to Lantheus?

Summary

How does HUTCHMED compare to Liquidia?

Summary

How does HUTCHMED compare to Amneal Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCM vs. The Competition

HUTCHMED Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

HUTCHMED (HCM) Competitors

HCM vs. CRNX, BLTE, LNTH, LQDA, and AMRX

How does HUTCHMED compare to Crinetics Pharmaceuticals?

Do institutionals and insiders have more ownership in HCM or CRNX?

Is HCM or CRNX more profitable?

Do analysts prefer HCM or CRNX?

Which has more risk & volatility, HCM or CRNX?

Which has stronger earnings & valuation, HCM or CRNX?

Does the media favor HCM or CRNX?

Summary

How does HUTCHMED compare to Belite Bio?

Which has more risk and volatility, BLTE or HCM?

Is BLTE or HCM more profitable?

Which has preferable valuation & earnings, BLTE or HCM?

Do analysts prefer BLTE or HCM?

Do institutionals & insiders have more ownership in BLTE or HCM?

Does the media prefer BLTE or HCM?

Summary

How does HUTCHMED compare to Lantheus?

Do institutionals and insiders believe in LNTH or HCM?

Which has more risk & volatility, LNTH or HCM?

Is LNTH or HCM more profitable?

Does the media refer more to LNTH or HCM?

Do analysts prefer LNTH or HCM?

Which has higher earnings & valuation, LNTH or HCM?

Summary

How does HUTCHMED compare to Liquidia?

Which has more risk & volatility, LQDA or HCM?

Do institutionals and insiders believe in LQDA or HCM?

Does the media prefer LQDA or HCM?

Do analysts prefer LQDA or HCM?

Is LQDA or HCM more profitable?

Which has better earnings and valuation, LQDA or HCM?

Summary

How does HUTCHMED compare to Amneal Pharmaceuticals?

Does the media refer more to HCM or AMRX?

Do institutionals & insiders hold more shares of HCM or AMRX?

Which has higher valuation & earnings, HCM or AMRX?

Do analysts prefer HCM or AMRX?

Is HCM or AMRX more profitable?

Which has more risk and volatility, HCM or AMRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

HCM vs. The Competition

HUTCHMED Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools